Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
August 03, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs,...
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
July 28, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
July 24, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2020 19:59 ET
|
Protara Therapeutics, Inc.
NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, Thursday, July 2nd, by Protara Therapeutics, Inc. (Nasdaq: TARA), please note that in the first...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2020 16:05 ET
|
Protara Therapeutics, Inc.
NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2020 16:05 ET
|
Protara Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
May 26, 2020 08:30 ET
|
Protara Therapeutics, Inc.
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
May 13, 2020 08:00 ET
|
Protara Therapeutics, Inc.
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
May 11, 2020 08:38 ET
|
ArTara Therapeutics
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty...
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2020 16:05 ET
|
ArTara Therapeutics
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with...